Significant Contract Modifications ($10M+) — September 03, 2026

Walgreens secured a fully obligated $290.9 million firm-fixed-price contract from the CDC, providing high revenue certainty through May 2025. The competitive award underscores Walgreens' capability in specialized medical support services.

The firm-fixed-price structure transfers cost overrun risk to Walgreens, which could pressure margins if operational costs exceed expectations.

The contract is tied to the CDC's ICATT program; any budget cuts or reallocation in FY2025/FY2026 could impact follow-on awards or contract extensions.

The $290.9M contract represents a significant portion of Walgreens' government services revenue, creating concentration risk if the program is not renewed.

The CDC's continued funding of specialized medical support under ICATT suggests potential for follow-on contracts or expanded scope, benefiting Walgreens and other providers.

The CDC's $290.9M award to Walgreens highlights increasing reliance on private sector partners for specialized medical support, a trend likely to continue as public health needs evolve.

{"entity" => "Walgreens Boots Alliance", "reason" => "Large contract provides revenue visibility; future growth depends on renewals and follow-on awards.", "trigger" => "Q2 2025 earnings call for contract performance updates; CDC ICATT re-compete announcement"}

{"entity" => "CDC", "reason" => "Budget allocations for ICATT will determine future contract opportunities.", "trigger" => "FY2025/FY2026 budget release and ICATT program funding announcements"}

{"entity" => "Competitors in public health services", "reason" => "Full and open competition indicates potential for market share shifts.", "trigger" => "Announcements of similar CDC contracts to other providers"}